22 Sep 2016 07:00
22 September 2016
Notice of Results
London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six months ending 30 June 2016 on Tuesday 27 September 2016.
Silence Therapeutics plc | Tel: +44 (0)20 3457 6900 |
Ali Mortazavi, Chief Executive Officer | |
David Ellam, Chief Financial Officer | |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) | Tel: +44 (0)20 7523 8350 |
Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel | |
Peel Hunt LLP (Joint Broker) | Tel: +44 (0)20 7418 8900 |
James Steel/Oliver Jackson | |
Media Enquiries: | Tel: +44 (0) 20 3727 1000 |
FTI Consulting | |
Simon Conway/Brett Pollard/Stephanie Cuthbert |
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.
SLN.L (SLN)